LABORATOIRE POUR LA SANTE ANIMALE : revenue, balance sheet and financial ratios

LABORATOIRE POUR LA SANTE ANIMALE is a French company founded 8 years ago, specialized in the sector Vente à distance sur catalogue spécialisé. Based in NEUILLY-SUR-SEINE (92200), this company of category PME shows in 2024 a revenue of 4.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - LABORATOIRE POUR LA SANTE ANIMALE (SIREN 832739965)
Indicator 2024 2023 2022 2021 2020 2019
Revenue 4 171 229 € 3 413 089 € 2 513 756 € 1 628 241 € 1 155 725 € 847 289 €
Net income -1 745 565 € -1 326 992 € -2 281 262 € -1 947 831 € -1 739 782 € -1 218 870 €
EBITDA 10 094 € 214 540 € -1 360 659 € -1 053 873 € -839 163 € -616 753 €
Net margin -41.8% -38.9% -90.8% -119.6% -150.5% -143.9%

Revenue and income statement

In 2024, LABORATOIRE POUR LA SANTE ANIMALE achieves revenue of 4.2 M€. Over the period 2019-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +37.5%. Vs 2023, growth of +22% (3.4 M€ -> 4.2 M€). After deducting consumption (2.0 M€), gross margin stands at 2.1 M€, i.e. a rate of 51%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 10 k€, representing 0.2% of revenue. Warning negative scissor effect: despite revenue change (+22%), EBITDA varies by -95%, reducing margin by 6.0 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Net income is negative at -1.7 M€ (-41.8% of revenue), which will impact equity.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

4 171 229 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

2 127 484 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

10 094 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-1 366 300 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-1 745 565 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

0.2%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at -611%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -15%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

-610.631%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

-15.356%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-8.847%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-24.915

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

45.2%

Solvency indicators evolution
LABORATOIRE POUR LA SANTE ANIMALE

Sector positioning

Debt ratio
-610.63 2024
2022
2023
2024
Q1: 0.0
Med: 3.84
Q3: 53.12
Excellent -50 pts over 3 years

In 2024, the debt ratio of LABORATOIRE POUR LA SANTE... (-610.63) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
-15.36% 2024
2022
2023
2024
Q1: 0.0%
Med: 20.06%
Q3: 53.53%
Average -17 pts over 3 years

In 2024, the financial autonomy of LABORATOIRE POUR LA SANTE... (-15.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
-24.91 years 2024
2022
2023
2024
Q1: -0.0 years
Med: 0.0 years
Q3: 0.38 years
Excellent

In 2024, the repayment capacity of LABORATOIRE POUR LA SANTE... (-24.91) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 122.91. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 3699.4x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

122.907

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

3699.396

Liquidity indicators evolution
LABORATOIRE POUR LA SANTE ANIMALE

Sector positioning

Liquidity ratio
122.91 2024
2022
2023
2024
Q1: 109.05
Med: 201.82
Q3: 390.18
Average

In 2024, the liquidity ratio of LABORATOIRE POUR LA SANTE... (122.91) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
3699.4x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.0x
Q3: 0.3x
Excellent +50 pts over 3 years

In 2024, the interest coverage of LABORATOIRE POUR LA SANTE... (3699.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 49 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 107 days. Excellent situation: suppliers finance 58 days of the operating cycle (retail model). Inventory turnover is 120 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 202 days of revenue, i.e. 2.3 M€ to permanently finance. Over 2019-2024, WCR increased by +267%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

2 342 562 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

49 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

107 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

120 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

202 j

WCR and payment terms evolution
LABORATOIRE POUR LA SANTE ANIMALE

Positioning of LABORATOIRE POUR LA SANTE ANIMALE in its sector

Comparison with sector Vente à distance sur catalogue spécialisé

Valuation estimate

Based on 121 transactions of similar company sales (all years), the value of LABORATOIRE POUR LA SANTE ANIMALE is estimated at 442 373 € (range 253 580€ - 953 979€). With an EBITDA of 10 094€, the sector multiple of 3.2x is applied. The price/revenue ratio is 0.27x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
121 transactions
253k€ 442k€ 953k€
442 373 € Range: 253 580€ - 953 979€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
10 094 € × 3.2x
Estimation 32 155 €
14 049€ - 74 469€
Revenue Multiple 30%
4 171 229 € × 0.27x
Estimation 1 126 071 €
652 800€ - 2 419 831€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 121 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Vente à distance sur catalogue spécialisé)

Compare LABORATOIRE POUR LA SANTE ANIMALE with other companies in the same sector:

Voir toutes les statistiques du secteur Vente à distance sur catalogue spécialisé

Frequently asked questions about LABORATOIRE POUR LA SANTE ANIMALE

What is the revenue of LABORATOIRE POUR LA SANTE ANIMALE ?

The revenue of LABORATOIRE POUR LA SANTE ANIMALE in 2024 is 4.2 M€.

Is LABORATOIRE POUR LA SANTE ANIMALE profitable?

LABORATOIRE POUR LA SANTE ANIMALE recorded a net loss in 2024.

Where is the headquarters of LABORATOIRE POUR LA SANTE ANIMALE ?

The headquarters of LABORATOIRE POUR LA SANTE ANIMALE is located in NEUILLY-SUR-SEINE (92200), in the department Hauts-de-Seine.

Where to find the tax return of LABORATOIRE POUR LA SANTE ANIMALE ?

The tax return of LABORATOIRE POUR LA SANTE ANIMALE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does LABORATOIRE POUR LA SANTE ANIMALE operate?

LABORATOIRE POUR LA SANTE ANIMALE operates in the sector Vente à distance sur catalogue spécialisé (NAF code 47.91B). See the 'Sector positioning' section above to compare the company with its competitors.